TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
6.89
+0.25 (3.77%)
Dec 31, 2025, 11:42 AM EST - Market open
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 2 analysts that cover TriSalus Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $11.5, which forecasts a 66.91% increase in the stock price over the next year. The lowest target is $11 and the highest is $12.
Price Target: $11.5 (+66.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TriSalus Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +74.17% | Dec 17, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +59.65% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +59.65% | Jan 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $10 | Buy | Initiates | $10 | +45.14% | Dec 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +59.65% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
45.64M
from 29.43M
Increased by 55.06%
Revenue Next Year
66.65M
from 45.64M
Increased by 46.04%
EPS This Year
-1.64
from -1.31
EPS Next Year
-0.22
from -1.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 47.6M | 75.1M | ||||
| Avg | 45.6M | 66.6M | ||||
| Low | 43.1M | 60.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 61.6% | 64.6% | ||||
| Avg | 55.1% | 46.0% | ||||
| Low | 46.5% | 32.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.89 | -0.04 | |
| Avg | -1.64 | -0.22 | |
| Low | -1.75 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.